Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma.
作者信息
Barman Pranab M, Su Grace L
机构信息
Department of Gastroenterology Northwestern University Feinberg School of Medicine Chicago IL.
Department of Gastroenterology VA Ann Arbor Healthcare System Ann Arbor MI.
出版信息
Clin Liver Dis (Hoboken). 2016 Feb 26;7(2):32-35. doi: 10.1002/cld.530. eCollection 2016 Feb.
Abstract
摘要
相似文献
1
Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma.巴塞罗那临床肝癌分期系统的局限性，重点关注经动脉化疗栓塞术作为肝细胞癌治疗的关键方式。
Clin Liver Dis (Hoboken). 2016 Feb 26;7(2):32-35. doi: 10.1002/cld.530. eCollection 2016 Feb.
2
DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.经动脉化疗栓塞术治疗中晚期肝癌——巴西一家癌症中心的初步经验
Cancer Imaging. 2017 Feb 6;17(1):5. doi: 10.1186/s40644-017-0108-6.
3
Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis.通过生存分析对最近提出的巴塞罗那临床肝癌B期亚分类进行临床评估。
J Gastroenterol Hepatol. 2014 Apr;29(4):787-93. doi: 10.1111/jgh.12452.
4
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.经动脉化疗栓塞术在肝细胞癌治疗中的应用：巴塞罗那临床肝癌分期系统
World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327.
5
Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.巴塞罗那临床肝癌分期0/A期切除术后复发性肝细胞癌经动脉化疗栓塞术与射频消融术的回顾性对比研究
J Vasc Interv Radiol. 2016 Dec;27(12):1829-1836. doi: 10.1016/j.jvir.2016.06.010. Epub 2016 Aug 21.
6
Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.原发性肝细胞癌患者的肿瘤分期及初始治疗方式分布
Clin Transl Oncol. 2017 Jul;19(7):891-897. doi: 10.1007/s12094-017-1621-6. Epub 2017 Feb 3.
7
Prevalence and Risk Factors of Post-chemoembolization Syndrome After Chemo-Embolization for Hepatocellular Carcinoma in Thailand.泰国肝细胞癌化疗栓塞术后化疗栓塞综合征的患病率及危险因素。
Dig Dis Sci. 2023 Sep;68(9):3818-3823. doi: 10.1007/s10620-023-08010-3. Epub 2023 Jul 4.
8
Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.经动脉化疗栓塞联合微波消融及阿帕替尼治疗巴塞罗那临床肝癌分期C期肝细胞癌患者：一项倾向评分匹配分析
J Cancer Res Ther. 2020;16(2):250-257. doi: 10.4103/jcrt.JCRT_345_19.
9
Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.经动脉化疗栓塞术治疗直径超过10厘米的巨大肝细胞癌：一项大型队列研究
Med Oncol. 2015 Mar;32(3):64. doi: 10.1007/s12032-015-0504-3. Epub 2015 Feb 15.
10
Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.载阿霉素超吸收性聚合物微球经导管动脉化疗栓塞治疗肝细胞癌的中期随访
J Vasc Interv Radiol. 2014 Feb;25(2):248-55.e1. doi: 10.1016/j.jvir.2013.10.017. Epub 2013 Dec 2.
引用本文的文献
1
Validation of a Multiplex Hypermethylation-based Blood Test to Detect Hepatocellular Carcinoma: A Prospective Case-control Study.基于多重甲基化的血液检测用于检测肝细胞癌的验证：一项前瞻性病例对照研究。
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102578. doi: 10.1016/j.jceh.2025.102578. Epub 2025 Apr 12.
2
Liver resection for hepatocellular carcinoma beyond the BCLC: are multinodular disease, portal hypertension, and portal system invasion real contraindications?超出巴塞罗那临床肝癌分期（BCLC）标准的肝细胞癌肝切除术：多结节病变、门静脉高压和门静脉系统侵犯真的是禁忌证吗？
J Gastrointest Oncol. 2022 Dec;13(6):3123-3134. doi: 10.21037/jgo-22-833.
3
Scoring systems for the management of oncological hepato-pancreato-biliary patients.肿瘤性肝胰胆疾病患者管理的评分系统
Ann Hepatobiliary Pancreat Surg. 2022 Feb 28;26(1):17-30. doi: 10.14701/ahbps.21-113.
4
Clinical Profile and Treatment of Hepatocellular Carcinoma: A Single-Center Experience.肝细胞癌的临床特征与治疗：单中心经验
South Asian J Cancer. 2021 Apr;10(2):76-80. doi: 10.1055/s-0041-1729451. Epub 2021 Sep 4.
5
Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma.肝癌患者临床结局的真实世界数据：新加坡国立癌症中心肝细胞癌管理共识指南的前瞻性验证
Liver Cancer. 2021 Jun;10(3):224-239. doi: 10.1159/000514400. Epub 2021 Apr 7.
6
Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature.肝细胞癌预后评分的比较：一项为期10年的单中心经验及当前文献简要综述
World J Hepatol. 2020 Dec 27;12(12):1239-1257. doi: 10.4254/wjh.v12.i12.1239.
7
Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice.中期肝细胞癌的治疗：当前证据与临床实践
Semin Intervent Radiol. 2020 Dec;37(5):456-465. doi: 10.1055/s-0040-1719186. Epub 2020 Dec 11.
8
Study to evaluate the immunomodulatory effects of radiofrequency ablation compared to surgical resection for liver cancer.研究评估与手术切除相比，射频消融对肝癌的免疫调节作用。
J Cancer. 2018 Aug 6;9(17):3187-3195. doi: 10.7150/jca.25084. eCollection 2018.
9
Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.体成分预测经动脉化疗栓塞治疗的肝细胞癌患者的生存。
Cancer Res Treat. 2018 Apr;50(2):530-537. doi: 10.4143/crt.2017.156. Epub 2017 Jun 1.
本文引用的文献
1
Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.体成分预测经动脉化疗栓塞治疗的肝细胞癌患者的生存。
Cancer Res Treat. 2018 Apr;50(2):530-537. doi: 10.4143/crt.2017.156. Epub 2017 Jun 1.
2
Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma.身体成分特征可预测肝细胞癌患者的总生存期。
Clin Transl Gastroenterol. 2016 May 26;7(5):e172. doi: 10.1038/ctg.2016.31.
3
Transarterial chemoembolization: modalities, indication, and patient selection.经动脉化疗栓塞：方式、适应证和患者选择。
J Hepatol. 2015 May;62(5):1187-95. doi: 10.1016/j.jhep.2015.02.010. Epub 2015 Feb 12.
4
Treatment of intermediate-stage hepatocellular carcinoma.中晚期肝细胞癌的治疗。
Nat Rev Clin Oncol. 2014 Sep;11(9):525-35. doi: 10.1038/nrclinonc.2014.122. Epub 2014 Aug 5.
5
Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.接受经动脉化疗栓塞术的肝细胞癌患者的死亡预测因素
Dig Dis Sci. 2014 Nov;59(11):2821-5. doi: 10.1007/s10620-014-3247-7. Epub 2014 Jun 28.
6
Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.比较巴塞罗那临床肝癌分期 B 期患者行肝切除术后与经肝动脉化疗栓塞术后的长期生存情况。
PLoS One. 2013 Jul 9;8(7):e68193. doi: 10.1371/journal.pone.0068193. Print 2013.
7
Epidemiology of hepatocellular carcinoma: consider the population.肝细胞癌的流行病学：从人群角度考虑。
J Clin Gastroenterol. 2013 Jul;47 Suppl(0):S2-6. doi: 10.1097/MCG.0b013e3182872f29.
8
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.中危（BCLC B）期肝细胞癌患者的异质性：提出一种亚分类以促进治疗决策。
Semin Liver Dis. 2012 Nov;32(4):348-59. doi: 10.1055/s-0032-1329906. Epub 2013 Feb 8.
9
Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system.肝癌患者的体能状态：决定因素、预后影响及对巴塞罗那临床肝癌系统的改善作用。
Hepatology. 2013 Jan;57(1):112-9. doi: 10.1002/hep.25950.
10
Management of hepatocellular carcinoma: an update.肝细胞癌的管理：最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
Zotero 插件